Adjunctive Glycine for Obsessive Compulsive Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00405535
Recruitment Status : Completed
First Posted : November 30, 2006
Last Update Posted : December 16, 2016
Obsessive Compulsive Foundation
Information provided by:
Nathan Kline Institute for Psychiatric Research

Brief Summary:
The purpose of this study is to determine whether individuals with obsessive compulsive disorder who will take a preparation of the amino acid glycine in addition to their current treatment, may experience improvement in their symptoms.

Condition or disease Intervention/treatment
Obsessive Compulsive Disorder Drug: glycine Other: placebo

Detailed Description:
Individuals with obsessive compulsive disorder (OCD) often find inadequate relief, even with the best of currently available treatments. Some evidence suggests the the neurotransmitter glutamate may be a useful target for new treatments for OCD. The amino acid glycine, if given orally in adequate dosages, can have specific effects on one particular glutamate receptor molecule in the brain, that might be helpful with OC symptoms. This randomized, double-blind protocol will have study participants who suffer with OCD take either a glycine preparation or placebo for 12 weeks. Clinical measures (e.g., Y-BOCS, NIMH-OC) will be recorded at each visit to determine whether those taking the glycine experience clinical benefit.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Adjunctive Glycine for Obsessive Compulsive Disorder
Study Start Date : June 2004
Study Completion Date : December 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Glycine
U.S. FDA Resources

Arm Intervention/treatment
Experimental: A
glycine powder
Drug: glycine
Placebo Comparator: B
placebo powder
Other: placebo

Primary Outcome Measures :
  1. Y-BOCS (Yale-Brown Obsessive Compulsive Scale) [ Time Frame: 12 weeks after baseline ]

Secondary Outcome Measures :
  1. NIMC-OC scale [ Time Frame: 12 weeks after baseline ]
  2. CGI-Improvement [ Time Frame: 12 weeks after baseline ]
  3. QLS(Quality of Life Scale) [ Time Frame: 12 weeks after baseline ]
  4. Sheehan Disability Scale [ Time Frame: 12 weeks after baseline ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of OCD present for at least 1 year
  • Male or female, age 18 to 65
  • Stable medication regimen for 12 weeks prior to study entry
  • at least moderately severe OC symptoms

Exclusion Criteria:

  • Active substance use disorder within the last 6 months
  • Comorbid schizophrenia, schizoaffective disorder, bipolar disorder, tic disorder, Tourette Disorder, schizotypal personality disorder
  • Hoarding as the principal OCD symptom
  • Insulin-dependent diabetes mellitus
  • Pregnant or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00405535

United States, New York
The Nathan Kline Institute for Psychiatric Research
Orangeburg, New York, United States, 10962
Sponsors and Collaborators
Nathan Kline Institute for Psychiatric Research
Obsessive Compulsive Foundation
Principal Investigator: William M Greenberg, MD Nathan Kline Institute for Psychiatric Research

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00405535     History of Changes
Other Study ID Numbers: 04I/C06
First Posted: November 30, 2006    Key Record Dates
Last Update Posted: December 16, 2016
Last Verified: December 2016

Keywords provided by Nathan Kline Institute for Psychiatric Research:
Obsessive Compulsive Disorder

Additional relevant MeSH terms:
Compulsive Personality Disorder
Obsessive-Compulsive Disorder
Pathologic Processes
Personality Disorders
Mental Disorders
Anxiety Disorders
Glycine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs